Opens in a new tab
Monday, 16 November 2026
EVIDENCE. INTERPRETED.
Disease & Drugs

Clinical Trials

Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.

Advertisement · Remove ads
970 × 90

Latest in Clinical Trials

1,156 stories · every one Fact-Checked
Velinotamig BCMA CD3 T-cell engager showing early renal response and reduced disease activity in refractory systemic lupus erythematosus.Clinical TrialsCullinan Reports 4 Renal Responses With Velinotamig in Lupus StudyInterim Phase 1b/2a findings presented at ACR Convergence 2026 show that velinotamig achieved reported complete renal response thresholds in four patients within 24 weeks, while eight of nine…9 Nov 2026 · 4 min read
Fact-Checked
Aulos Bioscience imneskibart Phase 2 results in checkpoint inhibitor-refractory melanoma and lung cancerClinical TrialsAulos Reports 9.1-Month PFS with Imneskibart in MelanomaAulos Bioscience reports Phase 2 findings for imneskibart combinations in checkpoint inhibitor-refractory melanoma and NSCLC.6 Nov 2026 · 4 min read
Fact-Checked
Obsidian Therapeutics' investigational amsoki-cel TIL cell therapy for ICI-resistant advanced melanoma.Clinical TrialsObsidian’s Amsoki-cel Shows 67% ORR in ICI-Resistant MelanomaObsidian Therapeutics reported a 67% objective response rate with investigational TIL therapy amsoki-cel in ICI-resistant advanced melanoma.6 Nov 2026 · 4 min read
Fact-Checked
Gilead's Livdelzi (seladelpar) Phase 3 IDEAL trial results showing ALP normalization in patients with primary biliary cholangitis.Clinical TrialsGilead Reports 75.4% ALP Normalization With Livdelzi in IDEAL TrialGilead’s Phase 3 IDEAL study found that 75.4% of patients receiving Livdelzi (seladelpar) achieved the ALP normalization composite endpoint at Week 52, compared with 16.1% on placebo.6 Nov 2026 · 4 min read
Fact-Checked
Akeso's ivonescimab plus chemotherapy achieves 70.1% major pathological response in resectable non-small cell lung cancer.Clinical TrialsAkeso Reports Strong Pathological Responses With Ivonescimab in NSCLCAkeso’s Phase II study published in Nature Medicine reports a 70.1% major pathological response and 50.7% pathological complete response with perioperative ivonescimab plus chemotherapy in resectable NSCLC.6 Nov 2026 · 5 min read
Fact-Checked
Brii Bio BRII-179-based immune priming and combination therapy results in Phase 2 hepatitis B studiesClinical TrialsBrii Bio Shows Improved HBsAg Loss With BRII-179 Triple TherapyBrii Bio’s Phase 2 ENRICH and ENHANCE studies demonstrate HBsAg loss with BRII-179-based immune-priming regimens in chronic hepatitis B.6 Nov 2026 · 4 min read
Fact-Checked
IQIRVO elafibranor achieves 85.3% ALP normalization in patients with primary biliary cholangitis in the Phase III ELSPIRE study.Clinical TrialsIpsen Reports 85.3% ALP Normalization With IQIRVO in PBCIpsen’s IQIRVO (elafibranor) achieved ALP normalization in 85.3% of patients with primary biliary cholangitis at Week 52 in the Phase III ELSPIRE study, compared with 23.3% receiving placebo.…6 Nov 2026 · 4 min read
Fact-Checked
Zai Lab's investigational DLL3-targeting ADC zocilurtatug pelitecan showing antitumour activity in previously treated extrapulmonary neuroendocrine carcinomas.Clinical TrialsZai Lab Reports Broad Tumour Responses With Zocilurtatug in epNECZai Lab’s investigational DLL3-targeting ADC zocilurtatug pelitecan achieved a 40% confirmed objective response rate in previously treated extrapulmonary neuroendocrine carcinomas, with a median response duration of 5.6 months.…5 Nov 2026 · 4 min read
Fact-Checked
Caldera Therapeutics CLD-423 IL-23p19 TL1A and Qyuns IL-17 TL1A bispecific antibody pipeline expansionClinical TrialsCaldera Reports CLD-423 Data, Expands Pipeline Through Qyuns DealCaldera Therapeutics reported updated Phase 1a findings for its IL-23p19 × TL1A bispecific antibody CLD-423, supporting planned Phase 2 studies in inflammatory bowel disease.5 Nov 2026 · 5 min read
Fact-Checked
Amgen Repatha (evolocumab) associated with a 20% lower heart attack rate than ezetimibe in a real-world ASCVD study.Clinical TrialsAmgen Links Repatha to 20% Lower Heart Attack Rate Than EzetimibeAmgen reported real-world findings showing that Repatha (evolocumab) was associated with a 20% lower rate of fatal or nonfatal myocardial infarction than ezetimibe among 544,103 adults with atherosclerotic…5 Nov 2026 · 4 min read
Fact-Checked
Iksuda Therapeutics IKS03 CD19-directed antibody-drug conjugate under investigation for advanced B-cell non-Hodgkin lymphoma.Clinical TrialsIksuda Reports 53% Response Rate for IKS03 in B-Cell LymphomaIksuda Therapeutics reported a 53% objective response rate for its investigational CD19-directed ADC IKS03 in a Phase 1 study of heavily pretreated B-cell non-Hodgkin lymphoma.5 Nov 2026 · 4 min read
Fact-Checked
Citius Oncology LYMPHIR denileukin diftitox-cxdl Study 302 quality-of-life findings in relapsed or refractory cutaneous T-cell lymphoma.Clinical TrialsCitius Reports LYMPHIR Quality-of-Life Improvements in CTCLCitius Oncology reports exploratory quality-of-life findings from LYMPHIR Study 302, highlighting improvements in skin-related well-being, overall quality of life and sustained itch reduction among clinical responders with relapsed…5 Nov 2026 · 4 min read
Fact-Checked
Page 3 of 97